Marksans Pharma spurts 2.5% after USFDA approval

India Infoline News Service | Mumbai | October 18, 2016 17:19 IST

The company announced that USFDA has granted approval for an Abbreviated New Drug Application (ANDA) for Paricalcitol Capsules 1mcg, 2 mcg and 4 mcg.

Marksans Pharma
Marksans Pharma Ltd ended at Rs 54.6, up by Rs 1.35 or 2.54% from its previous closing of Rs 53.25 on the BSE after the company announced that USFDA has granted approval for an Abbreviated New Drug Application (ANDA) for Paricalcitol Capsules 1mcg, 2 mcg and 4 mcg.

Paricalcitol Capsules 1mcg, 2 mcg and 4 mcg are therapeutically equivalent to the reference listed drug Zemplar Capsules 1 mcg, 2 mcg and 4 mcg of Abbvie Inc.

The scrip opened at Rs 53.5 and touched a high and low of Rs 56 and Rs 53.1 respectively. A total of 6868328 (NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs 2179.6 crore.

The BSE group 'A' stock of face value Rs 1 touched a 52 week high of Rs 113.8 on 28-Dec-2015 and a 52 week low of Rs 33.45 on 01-Mar-2016. Last one week high and low of the scrip stood at Rs 54.2 and Rs 51.2 respectively.

The promoters holding in the company stood at 48.25 % while Institutions and Non-Institutions held 13.77 % and 37.98 % respectively.

The stock traded above its 200 DMA.

***Note: This is a NSE Chart

 

Advertisements

  • Get your free IIFL Demat & Trading A/c now...Click here
  • Get IIFL express personal loan disbursal in just 8* hours...Know More
  • Get the most detailed result analysis on the web - Real Fast!
  • Actionable & Award-Winning Research on 500 Listed Indian Companies.